CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration

British Journal of Ophthalmology

Volumn 96, Issue 2, 2012, Pages 208-212

  McKibbin, Martin ^a,b   Ali, Manir ^b   Bansal, Shveta ^a,b   Baxter, Paul D ^b   West, Kumi ^a   Williams, Grange ^b   Cassidy, Frances ^a   Inglehearn, Chris F ^b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

AGED; ARTICLE; CAUCASIAN; COMPLEMENT FACTOR H GENE; CONTROLLED STUDY; DISEASE COURSE; DRUG RESPONSE; FEMALE; GENE; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HIGH TEMPERATURE REQUIREMENT FACTOR A 1 GENE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RETINA MACULA AGE RELATED DEGENERATION; SINGLE NUCLEOTIDE POLYMORPHISM; SUBRETINAL NEOVASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR GENE; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; COMPLEMENT FACTOR H; FEMALE; FLUORESCEIN ANGIOGRAPHY; GENOTYPE; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; PILOT PROJECTS; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84856059368     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjo.2010.193680     Document Type: Article

References (28)

1. Bunce C, Wormald R. Leading causes of certification for blindness and partial sight in England & Wales. BMC Public Health 2006;6:58.
2. Yates JR, Moore AT. Genetic susceptibility to age related macular degeneration. J Med Genet 2000;37:83-7. (Pubitemid 30245889)
3. Yang Z, Camp NJ, Sun H, et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 2006;314:992-3. (Pubitemid 44749944)
4. Chen W, Xu W, Tao Q, et al. Meta-analysis of the association of the HTRA1 polymorphisms with the risk of age-related macular degeneration. Exp Eye Res 2009;89:292-300.
5. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science 2005;308:385-9. (Pubitemid 40530070)
6. Klaver CC, Kliffen M, van Duijn CM, et al. Genetic association of apolipoprotein E with age-related macular degeneration. Am J Hum Genet 1998;63:200-6. (Pubitemid 30428336)
7. Churchill AJ, Carter JG, Lovell HC, et al. VEGF polymorphisms are associated with neovascular age-related macular degeneration. Hum Mol Genet 2006;15:2955-61. (Pubitemid 44446814)
8. Haines JL, Schnetz-Boutaud N, Schmidt S, et al. Functional candidate genes in age-related macular degeneration: Significant association with VEGF, VLDLR, and LRP6. Invest Ophthalmol Vis Sci 2006;47:329-35. (Pubitemid 46780832)
9. Anon. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomised clinical trials-TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
10. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
11. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44. (Pubitemid 44511558)
12. Boyer DS, Antoszyk AN, Awh CC, et al. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:246-52. (Pubitemid 46172497)
13. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010;94:2-13.
14. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007;143:566-83.
15. Goverdhan SV, Hannan S, Newsom RB, et al. An analysis of the CFH Y402H genotype in AMD patients and controls from the UK, and response to PDT treatment. Eye (Lond) 2008;22:849-54. (Pubitemid 351850525)
16. Feng X, Xiao J, Longville B, et al. Complement factor H Y402H and C-reactive protein polymorphism and photodynamic therapy response in age-related macular degeneration. Ophthalmology 2009;116:1908-12.
17. Brantley MA Jr, Edelstein SL, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to photodynamic therapy. Eye (Lond) 2009;23:626-31.
18. Seitsonen SP, Jarvela IE, Meri S, et al. The effect of complement factor H Y402H polymorphism on the outcome of photodynamic therapy in age-related macular degeneration. Eur J Ophthalmol 2007;17:943-9. (Pubitemid 351262905)
19. Brantley MA Jr, Fang AM, King JM, et al. Association of complement factor H and LOC387715 genotypes with response of exudative age-related macular degeneration to intravitreal bevacizumab. Ophthalmology 2007;114:2168-73. (Pubitemid 350181136)
20. Nischler C, Oberkofler H, Ortner C, et al. Complement factor H Y402H gene polymorphism and response to intravitreal bevacizumab in exudative age-related macular degeneration. Acta Ophthalmol 2011;89:e344-9.
21. Lee AY, Raya AK, Kymes SM, et al. Pharmacogenetics of complement factor H (Y402H) and treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 2009;93:610-13.
22. McKay GJ, Silvestri G, Orr N, et al. VEGF and age-related macular degeneration. Ophthalmology 2009;116:1227. e1-3.
23. Immonen I, Seitsonen S, Tommila P, et al. Vascular endothelial growth factor gene variation and the response to photodynamic therapy in age-related macular degeneration. Ophthalmology 2010;117:103-8.
24. Chowers I, Meir T, Lederman M, et al. Sequence variants in HTRA1 and LOC387715/ARMS2 and phenotype and response to photodynamic therapy in neovascular age-related macular degeneration in populations from Israel. Mol Vis 2008;14:2263-71.
25. Nelson GW, Martin MP, Gladman D, et al. Heterozygote advantage in autoimmune disease: Hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol 2004;173:4273-6. (Pubitemid 39280654)
26. Chen H, Yang Z, Gibbs D, et al. Association of HTRA1 polymorphism and bilaterality in advanced age-related macular degeneration. Vision Res 2008;48:690-4.
27. Wickremasinghe SS, Xie J, Lim J, et al. Variants in the APOE Gene are associated with improved treatment outcome following anti-VEGF therapy for neovascular AMD. Invest Ophthalmol Vis Sci 2011;52:4072-9.
28. Dadgostar H, Ventura AA, Chung JY, et al. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology 2009;116:1740-7.